



# Venetoclax and Blinatumomab for adult patients with relapsed/refractory or MRD positive Ph-negative B-cell precursor ALL: phase I part of the GMALL-BLIVEN trial

Lars Fransecky<sup>1,2</sup>, Walter Fiedler<sup>3</sup>, Christoph Röhlig<sup>4</sup>, Tim Sauer<sup>5</sup>, Simon Raffel<sup>5</sup>, Winfried Alsdorf<sup>3</sup>, Lisa Heberling<sup>4</sup>, Britta Steer<sup>1,2</sup>, Karin Huber<sup>1,2,6</sup>, Tim Versteegen<sup>1,2</sup>, Lea Spory<sup>1,2</sup>, Dorothee Deckbar<sup>7</sup>, Lena Reiser<sup>7</sup>, Sonja Bendig<sup>1,2,6</sup>, Lorenz Bastian<sup>1,2,6</sup>, Cecilia Bozzetti<sup>1,2</sup>, Thomas Beder<sup>1,2</sup>, Martin Neumann<sup>1,2,6</sup>, Monika Brüggemann<sup>1,2,6</sup>, Nicola Gökbüget<sup>7</sup> & Claudia Baldus<sup>1,2,6</sup>

<sup>1</sup> Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany, <sup>2</sup> University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany, <sup>3</sup> Department of Oncology and Hematology with Section Pneumology, University Medical Center Hamburg-Eppendorf, University Cancer Center Hamburg, Hamburg, Germany, <sup>4</sup> Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany, <sup>5</sup> Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany, <sup>6</sup> Clinical Research Unit "CATCH ALL" (KFO 5010) funded by the Deutsche Forschungsgemeinschaft, Bonn, Germany, <sup>7</sup> Department of Internal Medicine II, Hematology and Oncology, Goethe University Hospital Frankfurt, Frankfurt, Germany



Primary objective: safety  
Primary endpoint: **RP2D Venetoclax 800 mg/d**  
Secondary endpoint: **MOL-CR 56%**

**“Venetoclax combined with Blinatumomab is safe and feasible in adults with r/r or MRD-positive B-ALL”**